The University of Southampton
University of Southampton Institutional Repository

Advances in atopic dermatitis

Advances in atopic dermatitis
Advances in atopic dermatitis
Atopic dermatitis (AD) is a common inflammatory skin disease characterised by itch and is responsible for significant reduction in quality of life. While AD primarily arises in those under the age of 2 years, it is frequently persistent into adulthood. Recognition of AD is important for the general physician, especially to distinguish causes of acute flares that may present in any medical setting, such as eczema herpeticum and associated allergic reactions. While, to date, treatments have largely focused on broad spectrum immunomodulation with corticosteroids or systemic therapies (such as ciclosporin and methotrexate), increased knowledge in the pathophysiology of the disease has recently led to the expansion of treatment options available for those suffering with AD, and the new drugs on the horizon promise a previously unimagined potential for effective and safe treatment.

1470-2118
177 - 181
Ardern-Jones, Michael
7ac43c24-94ab-4d19-ba69-afaa546bec90
Plant, Alice
afc8ebf8-5834-4a8c-813e-a825b2b86a8f
Ardern-Jones, Michael
7ac43c24-94ab-4d19-ba69-afaa546bec90
Plant, Alice
afc8ebf8-5834-4a8c-813e-a825b2b86a8f

Ardern-Jones, Michael and Plant, Alice (2021) Advances in atopic dermatitis. Clinical Medicine, 177 - 181. (doi:10.7861/clinmed.2021-0280).

Record type: Article

Abstract

Atopic dermatitis (AD) is a common inflammatory skin disease characterised by itch and is responsible for significant reduction in quality of life. While AD primarily arises in those under the age of 2 years, it is frequently persistent into adulthood. Recognition of AD is important for the general physician, especially to distinguish causes of acute flares that may present in any medical setting, such as eczema herpeticum and associated allergic reactions. While, to date, treatments have largely focused on broad spectrum immunomodulation with corticosteroids or systemic therapies (such as ciclosporin and methotrexate), increased knowledge in the pathophysiology of the disease has recently led to the expansion of treatment options available for those suffering with AD, and the new drugs on the horizon promise a previously unimagined potential for effective and safe treatment.

Text
177.full - Version of Record
Restricted to Repository staff only
Request a copy

More information

Published date: 1 May 2021

Identifiers

Local EPrints ID: 454724
URI: http://eprints.soton.ac.uk/id/eprint/454724
ISSN: 1470-2118
PURE UUID: fc5ec31a-7e41-491e-864d-4af53facad9d
ORCID for Michael Ardern-Jones: ORCID iD orcid.org/0000-0003-1466-2016

Catalogue record

Date deposited: 22 Feb 2022 17:31
Last modified: 17 Mar 2024 03:10

Export record

Altmetrics

Contributors

Author: Alice Plant

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×